Heidelberg Pharma GmbH - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Heidelberg Pharma GmbH - Pharmaceuticals & Healthcare - Deals and Alliances Profile


  • Products Id :- GDPH137405D
  • |
  • Pages: 21
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Heidelberg Pharma GmbH (Heidelberg), formerly Heidelberg Pharma AG, a subsidiary of Wilex AG, is a drug development company that develops antibody-drug conjugates. The company's services include contract research service, in vivo pharmacology, molecular biology, quality assurance, bioanalytical services and others. It offers pre-clinical profiling of small molecules or biologicals intended for the treatment of cancer or inflammatory diseases. Heidelberg's new antibody-drug conjugates (ADCs) technology is developed to treat multiresistant tumors and dormant or quiescent tumor cells, which are regarded as a main reason for metastasis and resistance. The company serves pharmaceutical and biotechnology companies. Heidelberg is headquartered in Ladenburg, Germany.

Heidelberg Pharma GmbH-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Heidelberg Pharma GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Heidelberg Pharma GmbH, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Heidelberg Pharma GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Heidelberg Pharma GmbH, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Heidelberg Pharma GmbH, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Heidelberg Pharma GmbH, Pharmaceuticals & Healthcare, Deal Details 10

Partnerships 10

Heidelberg Pharma Enters into Research Agreement with Takeda Pharma 10

Nordic Nanovector Enters into Research Agreement with Heidelberg Pharma 11

Heidelberg Pharma Enters into Agreement with Celonic 12

Advanced Proteome Therapeutics Enters into Agreement with Heidelberg Pharma 13

MabVax Therapeutics Enters into Co-Development Agreement with Heidelberg Pharma 14

Licensing Agreements 15

Heidelberg Pharma Exercises Option for Licensing Agreement with Max Delbruck Center 15

Equity Offering 16

Heidelberg Pharma Raises USD22.8 Million in Rights Offering of Shares 16

Debt Offering 17

Heidelberg Pharma Raises USD17.5 Million in Private Placement of Bonds 17

Heidelberg Pharma GmbH-Key Competitors 18

Heidelberg Pharma GmbH-Key Employees 19

Heidelberg Pharma GmbH-Locations And Subsidiaries 20

Head Office 20

Appendix 21

Methodology 21

About GlobalData 21

Contact Us 21

Disclaimer 21

List of Figures

Heidelberg Pharma GmbH, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Heidelberg Pharma GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Heidelberg Pharma GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Heidelberg Pharma GmbH, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Heidelberg Pharma GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Heidelberg Pharma GmbH, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Heidelberg Pharma GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Heidelberg Pharma GmbH, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

List of Tables

Heidelberg Pharma GmbH, Pharmaceuticals & Healthcare, Key Facts 2

Heidelberg Pharma GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Heidelberg Pharma GmbH, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Heidelberg Pharma GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Heidelberg Pharma GmbH, Deals By Therapy Area, 2012 to YTD 2018 8

Heidelberg Pharma GmbH, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Heidelberg Pharma Enters into Research Agreement with Takeda Pharma 10

Nordic Nanovector Enters into Research Agreement with Heidelberg Pharma 11

Heidelberg Pharma Enters into Agreement with Celonic 12

Advanced Proteome Therapeutics Enters into Agreement with Heidelberg Pharma 13

MabVax Therapeutics Enters into Co-Development Agreement with Heidelberg Pharma 14

Heidelberg Pharma Exercises Option for Licensing Agreement with Max Delbruck Center 15

Heidelberg Pharma Raises USD22.8 Million in Rights Offering of Shares 16

Heidelberg Pharma Raises USD17.5 Million in Private Placement of Bonds 17

Heidelberg Pharma GmbH, Key Competitors 18

Heidelberg Pharma GmbH, Key Employees 19

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Heidelberg Pharma GmbH, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license
Single User License
USD 250 INR 18093
Site License
USD 500 INR 36185
Corporate User License
USD 750 INR 54278

NEWSLETTER BY CATEGORY




Testimonials

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com